Abstracts tagged "Joint destruction and rheumatoid arthritis (RA)"

Abstract Number: 2574 • 2016 ACR/ARHP Annual Meeting
IL-22 As a Biomarker for Erosive Disease in Rheumatoid Arthritis
Jan Leipe, Hendrik Schulze-Koops and Alla Skapenko, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose: Consistent with models of experimental arthritis implicating IL-22 – in the development of joint destruction could previously demonstrate that elevated IL-22 serum levels were…
Abstract Number: 1532 • 2015 ACR/ARHP Annual Meeting
Occurrence of Valvular Heart Disease in Rheumatoid Arthritis: A Population Based Study
Tamanna Khullar¹, John P. Bois¹, Cynthia S. Crowson², Megan L. Krause³ and Rekha Mankad¹, ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of cardiovascular disease, particularly atherosclerosis and heart failure. However, little is known…
Abstract Number: 1557 • 2015 ACR/ARHP Annual Meeting
The Impact of Hindfoot Deformity on Disability of Korean Patients with Rheumatoid Arthritis
Hye-Jin Jeong¹, Il Woong Sohn¹, Seung Lee¹, Seung Taek Song¹, Soo-Kyung Cho² and Yoon-Kyoung Sung², ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) commonly involves the hindfoot, but this part is frequently overlooked when caring for patients with multiple joints pain and deformity. For…
Abstract Number: 1630 • 2015 ACR/ARHP Annual Meeting
Progressive Destruction of Large Joints in Patients with Rheumatoid Arthritis Treated with Biologic Agents
Arata Nakajima¹, Masato Sonobe² and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Many clinical trials have revealed that biologic agents inhibit destruction of small joints, however, there have been a few reports demonstrating their inhibitory effects…
Abstract Number: 1841 • 2014 ACR/ARHP Annual Meeting
Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, Josh Dixey⁴, Patrick Kiely⁵, David Walsh^6,7 and Adam Young^1,8, ¹School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁵Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: It is well-established that sustained high disease activity in RA results in worse outcomes. In reality many patients remain in low/moderate disease activity states,…
Abstract Number: 90 • 2014 ACR/ARHP Annual Meeting
Genetic Variants in IL-6, IL-10, C5-TRAF1 and FCRL3 and Progression of Joint Damage in Rheumatoid Arthritis; A Study on Six Cohorts
H.W. van Steenbergen¹, L. Rodriguez-Rodriguez², E. Berglin³, A. Zhernakova⁴, R. Knevel¹, J. Ivorra-Cortes⁵, T.W.J. Huizinga¹, B. Fernández-Gutiérrez⁶, P.K. Gregersen⁷, S. Rantapää-Dahlqvist⁸ and A.H.M. van der Helm-van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ³Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, ⁴Genetics, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology, University Hospital la Fe, Valencia, Spain, ⁶Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁷The Feinstein Institute for Medical Research, Manhasset, NY, ⁸Department of Public Health and Clinical Medicine/Rheumatology, Umeå University Hospital, Umeå, Sweden
Background/Purpose Understanding the mechanisms underlying the inter-individual differences in radiographic progression is relevant and heritability studies have shown that genetic factors explain part of these…
Abstract Number: 2259 • 2013 ACR/ARHP Annual Meeting
Does a Ratingen Score Of ≥ 3 At Disease Onset Define RA In ACR/EULAR 2010 Criteria Negative Patients?
Ruediger Mueller¹, Toni Kaegi¹, Sarah Haile² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: A EULAR task force has recently selected an evidence and consensus based definition of erosive disease defining rheumatoid arthritis (RA) in patients who do…
Abstract Number: 2660 • 2012 ACR/ARHP Annual Meeting
Progressive Radiographic Joint Damage in Established Rheumatoid Arthritis: Common and Strongly Associated with Seropositivity
Siri Lillegraven¹, Nancy A. Shadick², Zarif Jabbar-Lopez³, Anna Potapov³, Michelle A. Frits⁴, Christine K. Iannaccone⁴, Espen A. Haavardsholm¹, Tore K. Kvien⁵, Michael Weinblatt² and Daniel H. Solomon⁶, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: During the last decade, rheumatoid arthritis (RA) research has mainly focused on early disease, as it has become apparent that early and aggressive treatment…
Abstract Number: 1009 • 2012 ACR/ARHP Annual Meeting
A New Approach for Detecting Progressive Joint Damage Using 3D Imaging From High-Resolution Peripheral Quantitative Computed Tomography: Measuring Reproducibility
Cheryl Barnabe¹, Helen R. Buie², Michelle Kan², Susan G. Barr³, Liam Martin³ and Steven K. Boyd², ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²Mechanical Engineering, University of Calgary, Calgary, AB, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada
A New Approach for Detecting Progressive Joint Damage using 3D Imaging from High-Resolution Peripheral Quantitative Computed Tomography: Measuring Reproducibility Background/Purpose: Joint space narrowing is an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].